数字基础设施成为临床试验的"标配"
去中心化临床试验可穿戴设备市场正在进入一个数字基础设施不再是可选项、而是基础配置的新阶段。随着试验越来越去中心化、患者参与不再局限于临床站点，可穿戴技术正在实现持续性数据采集、提升试验效率。这种转变正在重塑数据采集、分析和利用的整个流程。
The decentralized trial wearable market is entering a phase where digital infrastructure is no longer optional but foundational to clinical research. As trials become more decentralized and patient participation extends beyond clinical sites, wearable technologies are enabling continuous data capture and improving trial efficiency.
市场在2025年达到$24.29亿，向$57.70亿（2030年）和$127.83亿（2035年）持续扩张，背后的长期需求非常强劲。
The decentralized trial wearable market reached $2,428.6 million in 2025 and is projected to expand significantly to $5,769.8 million by 2030, eventually reaching $12,782.5 million by 2035.
产品与渠道结构
智能手表以38.0%的份额（$9.23亿）主导市场，广泛的用户接受度和使用便捷性是关键优势。生物传感器凭借更高精度的生理和临床数据采集能力，正在成为增长最快的产品类别。
Smartwatches dominated the market in 2025, contributing 38.0% or $922.9 million. Biosensors are expected to grow at the fastest pace through 2030, driven by their ability to capture detailed physiological and clinical data with higher accuracy.
在线分销渠道以64.5%的份额（$15.66亿）占据主导，反映了临床试验中数字化部署的本质特征。制药公司以41.5%的份额（$10.07亿）为最大终端用户，合同研究组织（CRO）在推进采用可穿戴技术方面的增速更快。
Online distribution channels led the market in 2025, accounting for 64.5% or $1,565.7 million. Pharmaceutical companies held the largest share at 41.5% or $1,007.2 million.
技术与应用趋势
AI驱动的预测分析和自动化、物联网设备的持续监测、云平台的数据整合——这些技术正在提升试验的数据质量和执行效率。数字生物标志物的发展也在强化临床终点的评估能力。
The market is being shaped by advanced technologies including artificial intelligence enabling predictive insights and automation, IoT-powered devices supporting continuous monitoring, and cloud platforms improving data integration.
远程患者监测以38.3%的份额（$9.30亿）为最大应用场景，其增长也是最快的。这个品类在去中心化试验中的核心地位不容撼动。
Remote patient monitoring emerged as the leading application, contributing 38.3% or $930.4 million in 2025. This segment is also expected to grow the fastest.
区域竞争与市场机会
北美以44.2%的份额（$10.74亿）领先，强大的数字基础设施和早期采用为支撑。亚太地区增长最快。市场格局分散，前十大玩家占17.97%的份额，IQVIA、ICON、LabCorp、Signant Health、Clario等是关键参与者。
North America led with 44.2% or $1,073.9 million in 2025. The market remains fragmented, with the top 10 players accounting for 17.97%. Key players include IQVIA Holdings Inc., ICON Public Limited Company, and LabCorp Drug Development Inc.
到2030年，智能手表品类将新增$13.10亿，在线渠道贡献$24.99亿的增值，远程患者监测将新增$15.50亿。美国市场预计贡献$13.51亿的最大增量。企业通过构建集成化可穿戴生态系统、多传感器设备和全面的临床试验解决方案来保持竞争力。
Significant growth opportunities are expected across multiple segments by 2030. Smartwatches segment to add $1,310.2 million, online distribution to contribute $2,498.5 million, and remote patient monitoring to generate $1,550.2 million.
总结与展望
去中心化临床试验可穿戴设备市场正处于数字化浪潮的前沿。随着真实世界数据的重要性上升，以及试验成本和时间压缩需求的增长，可穿戴技术将更加深入地嵌入临床试验的每一个环节。
The decentralized trial wearable market continues to evolve as digital tools become central to clinical research. As real-world data gains importance and trial efficiency demands grow, wearable technologies will remain at the forefront of clinical innovation.
数据来源：The Business Research Company (TBRC) | www.thebusinessresearchcompany.com
关于The Business Research Company
The Business Research Company (TBRC)是一家领先的市场情报公司，在企业、市场与消费者研究领域享有盛誉。我们已发布超过17,500份报告，覆盖27个行业与60多个地区。我们的研究基于1,500,000个数据集、广泛的二手研究以及对行业领袖的独家访谈。
我们通过市场进入研究包、竞争对手追踪包、供应商与经销商包等专项服务，提供持续及定制化研究支持。
https://www.thebusinessresearchcompany.com
